Exploring Disease Indication & Endpoint Selection for Ophthalmic Gene Therapy Trials to Unlock Optimal Results
Time: 11:30 am
day: Conference Day Two
Details:
- Showcasing how to replicate LUXTERNA results in subsequent RPE65 gene therapies
- Identifying the ideal volume and best vehicle
- Evaluating promotor usage, injection point and AAV virus formulation
